Welcome to the new SBIR.gov, to assist in getting you situated with the system, a preview of the new login and registration process is available here. Please reach out to the website support team with any questions via sba.sbir.support@reisystems.com
Company
Portfolio Data
Back to Company SearchBLUEWILLOW BIOLOGICS INC
UEI: RL3UZ5ZDKFT8
Number of Employees: 13
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2004
6
Phase I Awards
6
Phase II Awards
100%
Conversion Rate
$1,251,784
Phase I Dollars
$10,536,955
Phase II Dollars
$11,788,739
Total Awarded
Awards
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein
Amount: $2,617,783 Topic: NIAID
ABSTRACT Respiratory syncytial virus (RSV) is extremely ubiquitous, with almost all humans acquiring the infection by the age of two. It is manifested by several secondary acute respiratory illnesses including bronchiolitis croup, bronchitis, pneumonia and the common cold. RSV does not elicit a protective immune response in humans, which results in recurrent infections in children and adults. Infants infected with RSV have a high risk of developing reactive airway disease, such as asthma, through adolescence. RSV pathogenesis in adults can lead to serious complications, including pneumonia, chronic obstructive pulmonary disease, congestive heart failure and asthma. The elderly population is at particularly high risk. These illnesses caused by RSV infection combine to represent a massive worldwide health risk and substantial financial burden to the global healthcare system. There is currently no approved vaccine available to prevent RSV infection or disease. In this SBIR Phase I proposal, BlueWillow Biologics will manufacture the cGMP seeds for producing the recombinant F-protein RSV subunit with a preserved pre-fusion conformation (PrFFP), which would enable future manufacturing of clinical material for intranasal PrFFP/NE01 vaccine. The innovative feature is the application of BlueWillow’s NanoVaxTM nanoemulsion mucosal adjuvant and delivery technology to formulate PrFFP as an intranasal vaccine. This new strategy will activate both systemic and mucosal immunity, a key protective immune response necessary to prevent viral entry and infection locally at the respiratory mucosa including the lungs. Previous RSV vaccines currently under development using F-protein antigens have been formulated for intramuscular delivery, which does not promote mucosal immunity and may compromise their effectiveness against RSV. Successful completion of this SBIR phase 1 proposal will provide the foundation for the clinical development and commercial release of the first mucosal NE-RSV vaccine on the market. We will execute the license agreement with NIH-VRC to obtain cGMP seeds of CHO-DG44 seeds for PrFFP production. Following which we will perform technology transfer from NIH-VRC to BlueWillow and master cell bank for future manufacturing will be established at CDMO. The novel combination of highly antigenic F protein in its pre-fusion conformation with our innovative NanoVaxTM nanoemulsion mucosal adjuvant technology will result in a safe and effective intranasal vaccine to prevent RSV infection and disease in the elderly. This commercial product will fulfill an enormous unmet medical need.
Tagged as:
SBIR
Phase II
2022
HHS
NIH
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein
Amount: $299,650 Topic: NIAID
ABSTRACTRespiratory syncytial virus (RSV) is extremely ubiquitous, with almost all humans acquiring the infection by the age of two.It is manifested by several secondary acute respiratory illnesses including bronchiolitis croup, bronchitis, pneumonia and the common cold.RSV does not elicit a protective immune response in humans, which results in recurrent infections in children and adults.Infants infected with RSV have a high risk of developing reactive airway disease, such as asthma, through adolescence.RSV pathogenesis in adults can lead to serious complications, including pneumonia, chronic obstructive pulmonary disease, congestive heart failure and asthma.The elderly population is at particularly high risk. These illnesses caused by RSV infection combine to represent a massive worldwide health risk and substantial financial burden to the global healthcare system.There is currently no approved vaccine available to prevent RSV infection or disease.In this SBIR Phase I proposal, BlueWillow Biologics will manufacture the cGMP seeds for producing the recombinant F-protein RSV subunit with a preserved pre-fusion conformation (PrFFP), which would enable future manufacturing of clinical material for intranasal PrFFP/NE01 vaccine. The innovative feature is the application of BlueWillow’s NanoVaxTM nanoemulsion mucosal adjuvant and delivery technology to formulate PrFFP as an intranasal vaccine.This new strategy will activate both systemic and mucosal immunity, a key protective immune response necessary to prevent viral entry and infection locally at the respiratory mucosa including the lungs. Previous RSV vaccines currently under development using F-protein antigens have been formulated for intramuscular delivery, which does not promote mucosal immunity and may compromise their effectiveness against RSV.Successful completion of this SBIR phase 1 proposal will provide the foundation for the clinical development and commercial release of the first mucosal NE-RSV vaccine on the market. We will execute the license agreement with NIH-VRC to obtain cGMP seeds of CHO-DG44 seeds for PrFFP production.Following which we will perform technology transfer from NIH-VRC to BlueWillow and master cell bank for future manufacturing will be established at CDMO. The novel combination of highly antigenic F protein in its pre-fusion conformation with our innovative NanoVaxTM nanoemulsion mucosal adjuvant technology will result in a safe and effective intranasal vaccine to prevent RSV infection and disease in the elderly. This commercial product will fulfill an enormous unmet medical need.Project Narrative Respiratory Syncytial Virus (RSV) is a common cause of upper and lower respiratory tract infections and immunocompromised individuals (e.g. infants, young children and elderly) are at particularly high risk of severe infection and disease.There is no FDA-approved vaccine currently available to treat RSV and other therapies have either limited efficacy and/or are plagued by adverse side-effects.In this proposal, we will apply our proprietary NanoVaxTM nanoemulsion adjuvant technology to enable future manufacturing of a potent RSV vaccine that is safe, and facilitates intranasal delivery to confer protective, mucosal immunity against the virus.
Tagged as:
SBIR
Phase I
2020
HHS
NIH
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
Amount: $2,980,942 Topic: NIAID
ABSTRACT Genital herpes simplex virus-2 (HSV-2) infections are a major public health problem affecting rt40 million people in the United States and rt500 million globally. HSV-2 infection is characterized by painful recurring, genital sores and this can coincide with considerable psychological distress. Transmission can occur during sexual contact and from mother to child during birth with fatal consequences. Although several vaccines have been shown to elicit strong neutralizing activity against the virus, there is currently no effective vaccine to prevent HSV-2. Recent research has shown that while systemic, humoral immunity is beneficial, co-induction of mucosal immunity is prerequisite for full protection. BlueWillow Biologics has established NanoVax®, a proprietary oil-in- water nanoemulsion (NE01) adjuvant technology, that is designed for intranasal immunization. We've demonstrated the ability of NE01 to augment the targeting of antigens to the immune system while safely eliciting potent humoral, mucosal and cellular immune responses, including balanced induction of Th1, Th2 and Th17 cells. This feature facilitates the development of efficacious vaccines that induce mucosal and cell mediated immunity for full protection against various respiratory and sexually transmitted pathogens, including HSV-2. To address this unmet medical need, BlueWillow Biologics is developing a novel, intranasal bivalent vaccine comprised of two HSV-2 glycoproteins (gB2 and gD2) formulated in NE01. Our preclinical studies have shown that the resulting intranasal vaccine (IN) gB2/gD2-NE01 is an effective and commercially viable prophylactic strategy to prevent HSV-2 infections. We have optimized the processes for scale-up manufacturing of the antigens to achieve reproducible production of highly pure gB2 and gD2 drug substances at a scale sufficient to meet clinical demand. Importantly, we've demonstrated the prophylactic equivalency of the drug substances prepared from the established scale-up manufacturing processes to those we previously prepared at lab scale. This demonstrates our ability to manufacture high quantity of pure material while preserving the integrity and activities of the key vaccine components. In this Phase IIB SBIR program, BlueWillow Biologics will execute the remaining development work on the IN gB2/gD2-NE01 HSV-2 vaccine necessary to submit an investigational new drug (IND) application. Using the established scale-up processes established under Phase II, we will refine the gB2 expression process to improve yield, manufacture two batches of each antigen, along with the NE01 adjuvant, and dedicate the material towards completing an IND-enabling GLP toxicology study and formulating clinical material for stability assessment. The preparation of this material will enable a pre-IND meeting with the FDA to request feedback and approval of our GLP toxicology study design. Upon completion of the GLP toxicology study, BlueWillow will be ready to file an IND application and initiate a Phase 1 clinical trial (not covered under this funding).
Tagged as:
SBIR
Phase II
2020
HHS
NIH
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY. PHASE
Amount: $2,995,800 Topic: 72
Food allergy is an emerging health problem with increasing incidence and severity, particularly in children, and continuing throughout adulthood. Since 1990, the incidence of self-reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare system. With no approved therapeutics available, various forms of immunotherapy have been evaluated but generally do not facilitate long-term protection and can have adverse side effects. BlueWillow will apply its oil-in-water NanoVax nanoemulsion mucosal adjuvant (NE01) to formulate a vaccine against peanut allergy. In this SBIR project, Phase I will consist of formulation activities and the evaluation of efficacy in a mouse model of peanut allergy. In phase II, the project will assess the long-term protection in preclinical animal models and engage in IND-enabling activities.
Tagged as:
SBIR
Phase II
2020
HHS
NIH
Development of Nanvas TM (Oil in Water Nanoemulsion Adjuvant) Formulated Allergens as Intranasal Immunotherapeutic Vaccines for Peanut Allergy
Amount: $299,888 Topic: NIAID
Food allergy is an emerging health problem with increasing incidence and severityparticularly in childrenand continuing throughout adulthoodSincethe incidence of self reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare systemWith no approved therapeutics availablevarious forms of immunotherapy have been evaluated but generally do not facilitate long term protection and can have adverse side effectsBlueWillow will apply its novel oil in water NanoVax nanoemulsion mucosal adjuvantNEto formulate an intranasal vaccine against peanut allergyNEfacilitates modulation of existing THimmune responses to promote THTHimmunityIn this Fasttrack proposalPhase I will establish compatibilityshort term vaccine stability and protection in a mouse model of peanut allergyIn phase IIwe will establish and optimize processes for scale upclinical lot manufacturing and long term stability of both antigen and final vaccine formulationassess the longterm protection in preclinical animal modelshold a pre IND meeting with the FDAand conduct a GLP safety toxicity studySuccessful completion of this project will enable IND filing and initiation of clinical trials to assess the intranasal peanutNEvaccineThis Peanut NEvaccine will be the first commercial vaccine available for the treatment of peanut allergies to address a significant unmet medical need
Tagged as:
SBIR
Phase I
2019
HHS
NIH
Development of a nanoemulsion-based vaccine for chlamydia infection
Amount: $215,532 Topic: NIAID
AbstractChlamydia trachomatis is the most commonly reported bacterial infection in the United States and in many other parts of the worldBecause untreated infection in women causes long term problems with reproduction such as infertility and ectopic pregnancychlamydia has been the focus of public health control programs over the last two decadesCurrent antibiotic treatments have not halted the increased incidence and Ctrachomatis infections now cost the US health system $billion per annumDespite mathematical modelling highlighting that even a partially effective vaccine could reverse the increasing incidence of infection and that the medical and research fields agree that a vaccine will be required to control the current epidemica human chlamydial vaccine trial has not occurred in overyearsNanoBio Corporation has developed NanoStatadjuvant technologythat allows for both intranasal and intramuscular vaccine administrationproduce balanced humoral and cell mediated immune responses and offers a protection from a challenge in number of studies that include RSVpandemic influenza and pertussisIn addition to the balanced THThimmune response NEadjuvanted vaccines elicit strong Thresponse and humoral immunity in several species including humansagainst many different antigens when delivered intranasallyUsing NanoStatwe have shown that intranasalINimmunization of mice with the chlamydial major outer membrane proteinMOMPreduces the duration of infection and greatly reduces inflammatory oviduct damage following genital chlamydia infectionAdditionallyintramuscular immunization with MOMP NEdemonstrated the efficacy of this vaccine in decreasing both infection and pathology in mouse modelDrMahony has recently developed a novel and improved type III secretionT SSbased chlamydial vaccine antigenBDthat has yielded very promising results by reducing bacterial shedding byand upper genital tract pathology bywhich should be able to offer protection from multiple chlamydia serovars based on the highly conserved nature of the T SS proteinsFurthermorethe Ctrachomatis mouse model developed in DrMahony s laboratory recapitulates infections seen in humans with Ctrachomatis and thus are more relevant for evaluating the efficacy of chlamydia vaccinesas compared to Cmuridarum mouse models that are routinely used for chlamydia studiesThe preliminary data support further evaluation of an NE adjuvanted chlamydia vaccine to demonstrate protection against both infection and pathologyIn this proposalwe will utilize this newly developed Ctrachomatis mouse model and both intranasal and intramuscular applications of nanoemulsion adjuvanted BDvaccine to further develop and demonstrate the importance of NanoStatTM in preventing chlamydial disease and establish proof of concept necessary to initiate human clinical trials of a chlamydia vaccineThis project will identify an effective vaccine composition regiment and provide proof of concept data to seek SBIR Phase II funding to support further development of safe and efficacious chlamydia vaccine Project Narrative Chlamydia trachomatis is the most commonly reported bacterial infection in the United States and in many other parts of the worldUntreated infections in women are one of the major causes of infertility and ectopic pregnanciesDespite wide scale roll out of chlamydia control programs in the United StatesCanadaand Scandinaviareported cases of chlamydia did not declineCurrentlythere is no approved vaccine for chlamydiaThereforethe proposed studies will develop a novel nanoemulsion based vaccine using a using multi component antigenBDconsisting of the N terminalamino acids of Ctrachomatis CopBCopDand full length CTto prevent both infection and pelvic inflammatory diseasePIDDevelopment of a safe and highly effective nanoemulsion based vaccine against Chlamydia trachomatis would have great medical value for prevention of infection and its complications in the United States and worldwide
Tagged as:
SBIR
Phase I
2018
HHS
NIH
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine
Amount: $1,492,764 Topic: R
ABSTRACT Genital herpes simplex virusHSVinfections are a major public health problem affecting rtmillion people in the United States and rtmillion globallyHSVinfection causes recurringgenital sores that are painful and result in considerable psychological distressTransmission can occur during sexual contact and from mother to child during birth with fatal consequencesThere is no effective vaccine to prevent HSVNanoBio Corporation is developing a novelintranasal nanoemulsionNEvaccine that elicits serum neutralizing activitya Thresponseand Thcells for mucosal immunitythereby offering protection systemically and at the site of HSVentry through the mucosal surfaceThe proprietary oil in water NE has been shown to incorporatedeliver and adjuvant multiple different antigen types when administered by the intranasal routethus enabling broad protection against both respiratory and sexually transmitted diseasesThe NE adjuvant was formulated with protective gBand gDantigens for evaluation in the HSVguinea pig challenge modelData generated from two studies in this model demonstrated thatiIntranasal immunization conferred favorable protection following HSVchallenge compared tointramuscular administrationiiRobust protection was conferred even though intranasal immunization elicited lower serum antibody levelsindicating that additional mucosal immunity determinants are involvediiiIncorporation of two glycoproteinsgBand gDinto the NE vaccine was superior to gDantigen alonea finding not observed with previous intramuscular vaccine candidatesandivIntranasal immunization of the NE gBgDvaccine showed superior efficacy in the guinea pig model forprevention of infectionsheddingchronic recurrenceand viral latencyas compared to a conventionalintramuscular gDvaccine formulated in alum and monophosphoryl lipid AMPLThese data support the development of an intranasal NE gBgDvaccine to achieve protection against HSVIn this Direct Phase II SBIR programNanoBio will develop the research cell banks and the viral stock for production of gBand gDantigensand develop upstream and downstream processes for antigen productionpurification and scale up to producevaccine dosesgram purified antigenNanoBio simultaneously will develop the analytical methods required for final drug product releaseA pre IND meeting will be conducted with the FDAAfter completion of this SBIR projectfunding will be sought out to perform cGMP compliant production of the vaccineand an IND will be filed with the FDA to enable phase I II clinical trials to assess safetyimmunogenicity and preliminary efficacy of the NE vaccine to prevent HSVinfection in humansA prophylactic NE gBgDgenital herpes vaccine that induces both mucosal and systemic immunity will have great medical benefit in preventing HSVinfection in the United States and throughout the world
Tagged as:
SBIR
Phase II
2017
HHS
NIH
Nanoemulsion-based vaccine for chronic hepatitis B virus
Amount: $297,250 Topic: NIAID
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is the most common cause of chronic viral liver disease worldwide. More than 370 million people are chronically infected with HBV leading to nearly one million deaths annually as a result of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Currently available therapies against chronic HBV are expensive, require long-term administration over many years, and often fail to control viral persistence, replication and the progression of necro-inflammatory liver disease. These patients also have the potential for life-long spread of infection. A prophylactic vaccine would provide the best solution for prevention of hepatitis B virus infection. However, the current vaccines while generally effective are less useful in high-risk populations with renal disease or other immunological abnormalities. In addition, the current alum-based vaccine does not induce the type of cell-mediated immunity necessary to treat patients who cannot clear HBV. Therefore, current immunization strategies for hepatitis B cannot be employed as therapeutic vaccines. NanoBio Corporation (Ann Arbor, MI) and the University of Michigan, Michigan Nanotechnology Institute for Medicine and Biological Sciences are developing a nanoemulsion (NE) based adjuvant to enhance the immunogenicity and intranasal delivery of vaccine antigens. Nanoemulsion adjuvants are oil-in-water emulsions prepared by high speed homogenization using innocuous surfactants and solvents as stabilizers with an average droplet size of 200-600 nm. These adjuvants have been shown in animal models to augment targeting of vaccine antigens to the immune system while safely eliciting potent humoral and Th1-type cellular immune responses without inducing inflammation. In addition, the NE vaccine formulations for needle-free delivery are highly stable at room temperature enabling wide spread storage without refrigeration. The overall goal of the Phase I STTR program is to demonstrate that a nanoemulsion-based HBV vaccine can induce immune responses in the presence of confounding factors such as renal failure. This group is at high risk for complications of HBV infection when compared to normal individuals. Therefore, the studies will evaluate and optimize a novel NE-based intranasal vaccine for maximum HBV-specific CD4+ and CD8+ T-cell and humoral immune responses against hepatitis B surface antigen (HBsAg) in normal mice and in mice with chronic renal failure as a model for immune-impaired humans. A pre-clinical safety and tolerability study will be conducted in rabbits as a requirement for progression to human trials. After successful completion of the phase I program, a phase II STTR application will be prepared culminating in an FDA- approved phase I clinical trial to evaluate safety, dose range, immunogenicity and preliminary efficacy against chronic hepatitis B virus in humans with renal failure. In addition, these studies will provide the foundation for the use of this formulation as a therapeutic vaccine for chronically infected individuals. This new vaccine would have great value as a commercialized product to reduce the risk and associated financial burden of HBV- associated liver diseases and deaths both in the United States and globally. PUBLIC HEALTH RELEVANCE: Hepatitis B virus (HBV) is the most common cause of chronic viral liver disease. The proposed studies will develop a novel nanoemulsion-based intranasal vaccine to prevent viral transmission and development of severe complications such as cirrhosis, liver failure and hepatocellular carcinoma (HCC) in immune compromised and chronically infected patients. Development of a safe, needle-free, easy-to-administer and highly effective nanoemulsion-based vaccine would have great value for use as a therapeutic agent against chronic HBV infection in the United States and globally.
Tagged as:
STTR
Phase I
2010
HHS
NIH
Determine and Confirm the Field Use Protocol for NanoProject Non-Toxic Decontaminate for Facilities and Equipment Following a Bio-Incident
Amount: $224,666 Topic: 04-NCER-P4
NanoBio Corporation’s antimicrobial nanoemulsion technology was developed by Dr. James R. Baker at the University of Michigan Medical School over a period of 7 years. Research was funded through grants from the Defense Advanced Research Program Agency, which identified a need to have a nontoxic, noncorrosive biodefense decontaminate material that can decontaminate equipment, personnel, structures, and terrain in the event of a bioincident. A series of surfactant lipid nanoemulsions, which have extensive antimicrobial activity and are not toxic to tissues, resulted from this effort. Nanoemulsions are oil-in-water emulsions that employ droplets ranging from 200-800 nm. They are composed of detergents, vegetable oil, salt, water, and a food-grade alcohol, and for anthrax decontamination, a spore germination enhancer. The physical structure of the nanoemulsion contains the surfactants that mediate the antimicrobial activity. The emulsion droplet disrupts microorganisms through fusion and the destabilization of the cell membrane leading to lysis. In December 1999, the U.S. Army tested a broad spectrum nanoemulsion and nine other biodecontamination technologies in Dugway, Utah, against an anthrax surrogate, Bacillus globigii. Nanoemulsion was one of four technologies that proved effective and was the only nontoxic formulation available. Other tests against the vaccine strain of B. anthracis (Sterne strain) were conducted by the John Hopkins University Applied Physics Laboratory and by the U.S. Army Institute of Surgical Research. The Phase I research project funded by the U.S. Environmental Protection Agency (EPA) focused on optimization of NanoProtect™’s formulations for efficacy against B. anthracis and confirmation of product stability. The objective of this Phase II project is to confirm field use and post-use protocols for NanoProtect™ nontoxic decontamination for facilities and equipment following a bioincident. The most efficacious decontamination protocol will be determined through efficacy tests against Bacillus spores and other possible “bio-attack” pathogens. Tests will be conducted on materials typically found in buildings. Extended product stability tests will continue in parallel. The commercial application of the NanoProtect™ technology is that of a nontoxic, safe- for-humans, biodecontamination for standby emergency use by first responders. Customers will include federal, state, and local governments and distributors who will sell the product to corporations and consumers. NanoBio Corporation will provide sales and customer support, and a subcontractor will manufacture the product. NanoBio Corporation management has significant business experience applicable to the projects required for the commercial success of NanoProtect™. NanoBio Corporation is well funded for the commercialization of the products in its production pipeline.
Tagged as:
SBIR
Phase II
2005
EPA
Determine and Confirm the Field Use Protocol for NANOProtect ¿ Non-Toxic Decontaminate for Facilities and Equipment Following Bio Attack
Amount: $225,000
NanoBio Corporation¿s antimicrobial nanoemulsion technology was developed by Dr. James R. Baker at the University of Michigan Medical School over a period of seven years. Reschard was funded by grants for DARPA (Defense Advanced Research Program Agency), which identified a need to have a non-toxic, non-corrosive biodefence decon material that can decontaminated equipment, personnel, structures, and terrain in the event of a bio incident. A series of surfactant lipid nanoemulsions, which have extensive antimicrobial activity and are not toxic to tissues were resultant of this effort. Nanoemulsions are oil in water emulsions that employ droplets that range from 200-800 nanometers. They are composed of detergents, vegetable oil, salt, water, a food grade alcholol and for antrax decontamination a spore germination enhancer. The physical structure of the nanoemulsion contains the surfactants that mediate the antimicrobial activity. The emulsion droplet disrupts nicroorganisms through fusion and the destablixation of the cell membrane leading lysis. In December 1999 the U.S. Army tested a broad spectrum namoemulsion and nine other bio-decontamination technology at Dugway, Utah, against an Anthrax surrogate, Bacillus globigii. Nanoemulsions was one of four technologies that proved effective and the only non-toxic formulation available. Other tests against the vaccine strain of Bacillus anthracis (sterne strain) were conducted by John Hopkins University Applied Physics Lab and by the US Army Institute of Surgical Research. The Phase I SBIR focused on optimization of NanoProtectTM¿s formulations for efficacy against anthracis and on confirmation of product stability. The objective of Phase II SBIR project is to confirm field use and post-use protocols for NanoProtectTM non-toxic decontamination for facilities and equipment following bio-incident. The most efficacious decontamination protocol will be determined through efficacy tests against Bacillus spores and other possible bio-attack pathogens. Test will be conducted on materials typically found in buildings. Extended product stability test will continue in parallel. The commercial application of the technology, NanoProtectTM is that of a nontoxic, safe to humans, bio-decontamination for standby emergency use by first responders. Customers will include federal, state, local governments, and distributors who will sell to corporations and consumers. NanoBio will provide sales and customer support. A subcontractor will manufacture. NanoBio management has significant business experience applicable to the projects required for the commercial success of NanoProtectTM. Nano-Bio is will funded for the commercialization of the products in its¿ production pipeline.
Tagged as:
SBIR
Phase II
2005
EPA